We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost
Read MoreHide Full Article
Boston Scientific Corporation (BSX - Free Report) completed its $4.2-billion colossal acquisition of BTG plc within the expected time of closing. The acquisition is expected to considerably boost Boston Scientific's Peripheral Intervention (PI) portfolio.
BTG Acquisition at a Glance
BTG has three primary businesses, of which its Interventional Medicine portfolio, including various PI product lines, is the largest. The interventional oncology suite encompasses the TheraSphere Y-90 radiotherapy microspheres and the GALIL cryoablation system, which are used to treat liver, kidney and other cancer patients.
Furthermore, BTG's Interventional Medicine business also boasts a vascular portfolio, including filters, crossing catheters, microfoam and the EKOS Endovascular System.
In addition to BTG’s Interventional Medicine product lines, it also has a specialty pharmaceutical business, which includes acute care antidotes to treat overexposure to certain medications and toxins, and a licensing business that receives royalties related to BTG intellectual property and product license agreements.
A Strategic Deal
With the completion of BTG acquisition, the consolidated company now expects to gain an enhanced category leadership position in interventional oncology, arterial and venous therapies.
Business Selloff to Make Way for BTG
In its effort to accommodate the acquisition of BTG, Boston Scientific recently offloaded its certain non-prior businesses. The company has lately sold its portfolio of drug-loadable microsphere and bland embolic bead products to Varian Medical Systems for $90 million.
In addition, Boston Scientific is also initiating a process to explore the divestiture of the royalty stream associated with BTG's Zytiga licensing arrangements and expects to complete this divestiture by the end of 2019.
Price Performance
Shares of Boston Scientific have outperformed its industry in a year's time. The stock has returned 17.8% compared with the industry's 0.8% increase.
Medtronic’s long-term earnings growth rate is projected at 7.1%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
NuVasive’s long-term earnings growth rate is expected to be 12.8%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost
Boston Scientific Corporation (BSX - Free Report) completed its $4.2-billion colossal acquisition of BTG plc within the expected time of closing. The acquisition is expected to considerably boost Boston Scientific's Peripheral Intervention (PI) portfolio.
BTG Acquisition at a Glance
BTG has three primary businesses, of which its Interventional Medicine portfolio, including various PI product lines, is the largest. The interventional oncology suite encompasses the TheraSphere Y-90 radiotherapy microspheres and the GALIL cryoablation system, which are used to treat liver, kidney and other cancer patients.
Furthermore, BTG's Interventional Medicine business also boasts a vascular portfolio, including filters, crossing catheters, microfoam and the EKOS Endovascular System.
In addition to BTG’s Interventional Medicine product lines, it also has a specialty pharmaceutical business, which includes acute care antidotes to treat overexposure to certain medications and toxins, and a licensing business that receives royalties related to BTG intellectual property and product license agreements.
A Strategic Deal
With the completion of BTG acquisition, the consolidated company now expects to gain an enhanced category leadership position in interventional oncology, arterial and venous therapies.
Business Selloff to Make Way for BTG
In its effort to accommodate the acquisition of BTG, Boston Scientific recently offloaded its certain non-prior businesses. The company has lately sold its portfolio of drug-loadable microsphere and bland embolic bead products to Varian Medical Systems for $90 million.
In addition, Boston Scientific is also initiating a process to explore the divestiture of the royalty stream associated with BTG's Zytiga licensing arrangements and expects to complete this divestiture by the end of 2019.
Price Performance
Shares of Boston Scientific have outperformed its industry in a year's time. The stock has returned 17.8% compared with the industry's 0.8% increase.
Zacks Rank & Stocks to Consider
Boston Scientific currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are Medtronic (MDT - Free Report) , Baxter (BAX - Free Report) and NuVasive , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Medtronic’s long-term earnings growth rate is projected at 7.1%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
NuVasive’s long-term earnings growth rate is expected to be 12.8%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>